Dan Cooper

Vice President, Scientific Affairs, Pharmacoeconomics and Market Access

A pharmacist, pharmacoeconomist and pharmacoepidemiologist, Dr. Dan Cooper is passionate about science and population health. His rigour and global vision of the issues surrounding access to health innovations have allowed him to acquire a solid reputation in the world of drug and technology assessment. Dan’s analytical skills and expertise in establishing reimbursement and market access strategies are recognized at all levels of drug evaluation, including the negotiation of listing agreements. He offers a highly personalized and results-oriented service that allows him to maintain long-term relationships of trust with his clients.

Prior to joining TACT, Dan ran his own drug evaluation and pharmacoeconomic consulting firm, COOPERx Strategies Inc. and is the founder of the continuing education platform on optimal drug use, USOPRx.com, for healthcare and drug industry professionals. He also has a wealth of experience acquired through his responsibilities as a pharmacist and senior advisor in pharmacoeconomics at the Institut national d’excellence en santé et en services sociaux (INESSS), where he worked for nearly 10 years. During his years at the INESSS, he was responsible for pharmacoeconomic analyses and the review of the opinions formulated by the Institute for the Quebec Minister of Health and Social Services. In particular, he coordinated the revision of the evaluation frameworks for cancer drugs and those used for the treatment of rare diseases. Dan has also worked with the Canadian Agency for Drugs and Technologies in Health (CADTH) as a pharmacoeconomic expert. He still maintains academic collaborations; notably as the person in charge of an introduction to pharmacoeconomics course at Université Laval.

Dan developed his expertise in clinical and pharmacoeconomic analysis of drugs during his master’s and his Doctor of Pharmacy degrees, as well as during a postdoctoral research experience in oncology pharmacoeconomics. He also completed professional negotiation training at Harvard University, which broadened his skills in the drug price negotiation process.